Management of Asymptomatic HSV-2 Infection

Introduction to HSV-2 Management

The American College of Physicians and Infectious Diseases Society of America recommend that antiviral treatment is not routinely indicated for asymptomatic HSV-2 seropositive individuals, but suppressive therapy should be offered if they develop symptoms or wish to reduce transmission risk to sexual partners 1, 2
Approximately 20% of HSV-2 seropositive persons never recognize genital symptoms consistent with herpes, highlighting the importance of symptom-based management 1, 2

Routine antiviral treatment is not indicated for truly asymptomatic patients, as the IgG titer level does not change this recommendation 1, 2
Suppressive therapy can be considered for asymptomatic patients who wish to reduce transmission risk to sexual partners, as it works through suppression of viral shedding 1, 2
Suppressive therapy is not effective for reducing transmission among persons with HIV/HSV-2 coinfection 1, 2

All patients with symptomatic HSV-2 infection should be offered suppressive therapy as one of two management approaches, according to the Centers for Disease Control and Prevention 1, 2
Suppressive therapy reduces recurrence frequency by ≥75% among patients with frequent recurrences (≥6 per year), as recommended by the MMWR 3
Suppressive therapy also reduces transmission to sexual partners, as demonstrated in heterosexual couples, and applies to all populations through the same mechanism of viral shedding suppression 1, 2

The Centers for Disease Control and Prevention recommend valacyclovir 500 mg to 1 g daily, acyclovir 400 mg twice daily, or famciclovir 250 mg twice daily for suppressive therapy 3, 4
Safety and efficacy have been documented for up to 6 years of continuous therapy with acyclovir, according to the MMWR Recommendations and Reports 3

Asymptomatic viral shedding occurs even without visible lesions, and is more frequent with HSV-2 than HSV-1, highlighting the importance of comprehensive counseling 3, 4
Transmission can occur during asymptomatic periods, and condom use should be encouraged with all sexual partners, especially new or uninfected partners, as recommended by the CDC 3, 4
Childbearing-aged women must inform obstetric providers due to neonatal transmission risk, according to the American College of Obstetricians and Gynecologists 4, 5

The USPSTF recommends against screening for HSV-2 among asymptomatic adolescents and adults with low pretest probability, and treatment decisions should not be based on IgG titer levels alone 1, 2
Not all seropositive patients need treatment, only those with symptoms or specific transmission prevention goals benefit from suppressive therapy, as recommended by the Infectious Diseases Society of America 1, 2